

RECEIVED  
2/19/09  
CENTRAL FAX CENTER  
FEB 19 2009

<b>Address to:</b> Mail Stop M Correspondence Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 USA  <b>VIA FACSIMILE ONLY</b> 571-273-8300	<b>Application/Patent No.</b>	<b>7,196,197</b>
	<b>Docket No.</b>	<b>RN2050000</b>
	<b>Filing/Issue Date</b>	<b>March 27, 2007</b>
	<b>First Named Inventor</b>	<b>WANG, Zhi-Xian</b>
	<b>Title:</b>	<b>Process for the Preparation of Flecainide, Its Pharmaceutically Acceptable Salts And Important Intermediates Thereof</b>

THIS FACSIMILE TRANSMISSION CONTAINS A TOTAL OF  
**4 PAGES**  
 (INCLUDING THIS PAGE)

**OFFICIAL COMMUNICATION**

**CERTIFICATE OF FACSIMILE TRANSMISSION**

I hereby certify that this communication having 4 pages in total (1 page of fax cover page; 1 page of PTO/SB/80 and 1 supplemental page; 1 page of PTO/SB/96; is being facsimile transmitted to the Patent and Trademark Office (571-273-8300) on the date shown below.

Graham J. K. McKinnon  
Reg No.: 56,687

Signature

Date 19 Feb 2009

FEB 19 2009

PTO/SB/96 (12-08)

Approved for use through 01/31/2009. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**STATEMENT UNDER 37 CFR 3.73(b)**Applicant/Patent Owner: Apotex Pharmachem Inc.Application No./Patent No.: 7,196,197Filed/Issue Date: March 27, 2007Entitled: NOVEL PROCESS FOR THE PREPARATION OF FLECAINIDE, ITS PHARMACEUTICALLY ACCEPTABLE SALTS AND IMPORTANT INTERMEDIATES THEREOFApotex Pharmachem Inc. , a Corporation  
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1.  the assignee of the entire right, title, and interest; or
2.  an assignee of less than the entire right, title and interest  
(The extent (by percentage) of its ownership interest is \_\_\_\_\_ %)

in the patent application/patent identified above by virtue of either:


A.  An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy therefore is attached.

OR

B.  A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:1. From: Zhi-Xian WANG To: Brantford Chemicals Inc.The document was recorded in the United States Patent and Trademark Office at  
Reel 014503, Frame 0041, or for which a copy thereof is attached.2. From: Yuanquiang LI To: Brantford Chemicals Inc.The document was recorded in the United States Patent and Trademark Office at  
Reel 014503, Frame 0041, or for which a copy thereof is attached.3. From: Bhaskar Reddy GUNTOORI To: Brantford Chemicals Inc.The document was recorded in the United States Patent and Trademark Office at  
Reel 014503, Frame 0041, or for which a copy thereof is attached. Additional documents in the chain of title are listed on a supplemental sheet. As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.



Date

Graham J.K. McKinnon

416.749.9300

Printed or Typed Name

Telephone Number

Patent Agent

Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

4. From: Brantford Chemicals Inc. To: Apotex Pharmachem Inc.  
The document was recorded in the United States Patent and Trademark Office at  
Reel 015312 , Frame 0574 , or for which a copy thereof is attached.

FEB 19 2009

PTO/SB/80 (01-06)

Approved for use through 12/31/2008. OMB 0651-0035  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## POWER OF ATTORNEY TO PROSECUTE APPLICATIONS BEFORE THE USPTO

I hereby revoke all previous powers of attorney given in the application identified in the attached statement under 37 CFR 3.73(b).

I hereby appoint:

Practitioners associated with the Customer Number:

81399

OR

Practitioner(s) named below (if more than ten patent practitioners are to be named, then a customer number must be used):

Name	Registration Number	Name	Registration Number

as attorney(s) or agent(s) to represent the undersigned before the United States Patent and Trademark Office (USPTO) in connection with any and all patent applications assigned only to the undersigned according to the USPTO assignment records or assignment documents attached to this form in accordance with 37 CFR 3.73(b).

Please change the correspondence address for the application identified in the attached statement under 37 CFR 3.73(b) to:



The address associated with Customer Number:

81399

OR

<input type="checkbox"/> Firm or Individual Name			
Address			
City	State	Zip	
Country			
Telephone			Email

## Assignee Name and Address:

**Apotex Pharmachem Inc.**

34 Spalding Drive


Brantford, Ontario

Canada N3T 6B8

A copy of this form, together with a statement under 37 CFR 3.73(b) (Form PTO/SB/96 or equivalent) is required to be filed in each application in which this form is used. The statement under 37 CFR 3.73(b) may be completed by one of the practitioners appointed in this form if the appointed practitioner is authorized to act on behalf of the assignee, and must identify the application in which this Power of Attorney is to be filed.

## SIGNATURE of Assignee of Record

The individual whose signature and title is supplied below is authorized to act on behalf of the assignee

Signature		Date	August 6, 2008
Name	K.S. Keshava Murthy	Telephone	519-758-8942
Title	President		

This collection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.